| Literature DB >> 25438903 |
Masashi Fujino1, Masaharu Ishihara2, Satoshi Honda3, Shoji Kawakami3, Takafumi Yamane3, Toshiyuki Nagai3, Kazuhiro Nakao3, Tomoaki Kanaya3, Leon Kumasaka3, Yasuhide Asaumi3, Tetsuo Arakawa3, Yoshio Tahara3, Michio Nakanishi3, Teruo Noguchi3, Kengo Kusano1, Toshihisa Anzai1, Yoichi Goto3, Satoshi Yasuda1, Hisao Ogawa4.
Abstract
This study was undertaken to assess the impact of acute hyperglycemia (acute-HG) and chronic hyperglycemia (chronic-HG) on short-term outcomes in patients with acute myocardial infarction (AMI). This study consisted of 696 patients with AMI. Acute-HG was defined as admission plasma glucose ≥200 mg/dl and chronic-HG as hemoglobin A1c ≥6.5%. Acute-HG was associated with higher peak serum creatine kinase (4,094 ± 4,594 vs 2,526 ± 2,227 IU/L, p <0.001) and in-hospital mortality (9.8% vs 1.6%, p <0.001). On the contrary, there was no significant difference in peak creatine kinase (2,803 ± 2,661 vs 2,940 ± 3,181 IU/L, p = 0.59) and mortality (3.3 vs 3.7%, p = 0.79) between patients with chronic-HG and those without. Multivariate analysis showed that admission plasma glucose was an independent predictor of in-hospital mortality (odds ratio 1.15, 95% confidence interval 1.05 to 1.27, p <0.001), but hemoglobin A1c was not. When only patients with acute-HG were analyzed, chronic-HG was associated with a significantly smaller infarct size (3,221 ± 3,001 vs 5,904 ± 6,473 IU/L, p <0.001) and lower in-hospital mortality (5.5 vs 18.9%, p = 0.01). In conclusion, these results suggested that acute-HG, but not chronic-HG, was associated with adverse short-term outcomes after AMI. Paradoxically, in patients with acute-HG, chronic-HG might abate the adverse effects of acute-HG.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25438903 DOI: 10.1016/j.amjcard.2014.09.015
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778